CEFTRIAXONE SODIUM- ceftriaxone sodium injection, powder, for solution

Hospira, Inc

----------

Ceftriaxone for Injection, USP
ADD-Vantage® Vials

Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Ceftriaxone for injection, USP is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 72-(Z)-(O-methyloxime), disodium salt, sesquaterhydrate.

The chemical formula of ceftriaxone sodium is C18H16N8Na2O7S3•3.5H2O. It has a calculated molecular weight of 661.60 and the following structural formula:

![Chemical Structure of Ceftriaxone Sodium](image)

Ceftriaxone sodium is a white to yellowish crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7. The color of ceftriaxone sodium solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used.

Ceftriaxone sodium contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone activity.

CLINICAL PHARMACOLOGY

Average plasma concentrations of ceftriaxone following a single 30-minute intravenous (IV) infusion of a 0.5, 1 or 2 g dose and intramuscular (IM) administration of a single 0.5 (250 mg/mL or 350 mg/mL concentrations) or 1 g dose in healthy subjects are presented in Table 1.

<table>
<thead>
<tr>
<th>Dose/Route</th>
<th>Average Plasma Concentrations (mcg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5 hr</td>
</tr>
<tr>
<td>0.5 g IV*</td>
<td>82</td>
</tr>
<tr>
<td>0.5 g IM</td>
<td>22</td>
</tr>
</tbody>
</table>

Table 1. Ceftriaxone Plasma Concentrations After Single Dose Administration
Ceftriaxone was completely absorbed following IM administration with mean maximum plasma concentrations occurring between 2 and 3 hours post-dose. Multiple IV or IM doses ranging from 0.5 to 2 g at 12- to 24-hour intervals resulted in 15% to 36% accumulation of ceftriaxone above single dose values.

Ceftriaxone concentrations in urine are shown in Table 2.

**Table 2. Urinary Concentrations of Ceftriaxone After Single Dose Administration**

<table>
<thead>
<tr>
<th>Dose/Route</th>
<th>Average Urinary Concentrations (mcg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 to 2 hr</td>
</tr>
<tr>
<td>0.5 g IV</td>
<td>526</td>
</tr>
<tr>
<td>0.5 g IM</td>
<td>115</td>
</tr>
<tr>
<td>1 g IV</td>
<td>995</td>
</tr>
<tr>
<td>1 g IM</td>
<td>504</td>
</tr>
<tr>
<td>2 g IV</td>
<td>2692</td>
</tr>
</tbody>
</table>

ND = Not determined.

Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. After a 1 g IV dose, average concentrations of ceftriaxone, determined from 1 to 3 hours after dosing, were 581 mcg/mL in the gallbladder bile, 788 mcg/mL in the common duct bile, 898 mcg/mL in the cystic duct bile, 78.2 mcg/g in the gallbladder wall and 62.1 mcg/mL in the concurrent plasma.

Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour. Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL. Ceftriaxone crosses the blood placenta barrier.

The average values of maximum plasma concentration, elimination half-life, plasma clearance and volume of distribution after a 50 mg/kg IV dose and after a 75 mg/kg IV dose in pediatric patients suffering from bacterial meningitis are shown in Table 3. Ceftriaxone penetrated the inflamed meninges of infants and pediatric patients; CSF concentrations after a 50 mg/kg IV dose and after a 75 mg/kg IV dose are also shown in Table 3.

**Table 3. Average Pharmacokinetic Parameters of Ceftriaxone in Pediatric Patients With Meningitis**

<table>
<thead>
<tr>
<th></th>
<th>50 mg/kg IV</th>
<th>75 mg/kg IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum Plasma Concentrations (mcg/mL)</td>
<td>216</td>
<td>275</td>
</tr>
<tr>
<td>Elimination Half-life (hr)</td>
<td>4.6</td>
<td>4.3</td>
</tr>
</tbody>
</table>
Plasma Clearance (mL/hr/kg) | 49 | 60  
Volume of Distribution (mL/kg) | 338 | 373  
CSF Concentration – inflamed meninges (mcg/mL) | 5.6 | 6.4  
Range (mcg/mL) | 1.3 to 18.5 | 1.3 to 44  
Time after dose (hr) | 3.7 (± 1.6) | 3.3 (± 1.4)  

Compared to that in healthy adult subjects, the pharmacokinetics of ceftriaxone were only minimally altered in elderly subjects and in patients with renal impairment or hepatic dysfunction (Table 4); therefore, dosage adjustments are not necessary for these patients with ceftriaxone dosages up to 2 g per day. Ceftriaxone was not removed to any significant extent from the plasma by hemodialysis; in six of 26 dialysis patients, the elimination rate of ceftriaxone was markedly reduced.

### Table 4. Average Pharmacokinetic Parameters of Ceftriaxone in Humans

<table>
<thead>
<tr>
<th>Subject Group</th>
<th>Elimination Half-Life (hr)</th>
<th>Plasma Clearance (L/hr)</th>
<th>Volume of Distribution (L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy Subjects</td>
<td>5.8 to 8.7</td>
<td>0.58 to 1.45</td>
<td>5.8 to 13.5</td>
</tr>
<tr>
<td>Elderly Subjects (mean age, 70.5 yr)</td>
<td>8.9</td>
<td>0.83</td>
<td>10.7</td>
</tr>
<tr>
<td>Patients With Renal Impairment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemodialysis Patients (0 to 5 mL/min)*</td>
<td>14.7</td>
<td>0.65</td>
<td>13.7</td>
</tr>
<tr>
<td>Severe (5 to 15 mL/min)</td>
<td>15.7</td>
<td>0.56</td>
<td>12.5</td>
</tr>
<tr>
<td>Moderate (16 to 30 mL/min)</td>
<td>11.4</td>
<td>0.72</td>
<td>11.8</td>
</tr>
<tr>
<td>Mild (31 to 60 mL/min)</td>
<td>12.4</td>
<td>0.70</td>
<td>13.3</td>
</tr>
<tr>
<td>Patients With Liver Disease</td>
<td>8.8</td>
<td>1.1</td>
<td>13.6</td>
</tr>
</tbody>
</table>

* Creatinine clearance.

The elimination of ceftriaxone is not altered when ceftriaxone is co-administered with probenecid.

### Pharmacokinetics in the Middle Ear Fluid

In one study, total ceftriaxone concentrations (bound and unbound) were measured in middle ear fluid obtained during the insertion of tympanostomy tubes in 42 pediatric patients with otitis media. Sampling times were from 1 to 50 hours after a single intramuscular injection of 50 mg/kg of ceftriaxone. Mean (±SD) ceftriaxone levels in the middle ear reached a peak of 35 (±12) mcg/mL at 24 hours, and remained at 19 (±7) mcg/mL at 48 hours. Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated. Ceftriaxone is highly bound to plasma proteins. The extent of binding to proteins in the middle ear fluid is unknown.

### Interaction with Calcium

Two in vitro studies, one using adult plasma and the other neonatal plasma from umbilical cord blood have been carried out to assess interaction of ceftriaxone and calcium. Ceftriaxone concentrations up to 1 mM (in excess of concentrations achieved in vivo following administration of 2 grams ceftriaxone infused over 30 minutes) were used in combination with calcium concentrations up to 12 mM (48 mg/dL). Recovery of ceftriaxone from plasma was reduced with calcium concentrations of 6 mM (24 mg/dL) or higher in adult plasma or 4 mM (16 mg/dL) or higher in neonatal plasma. This may be reflective of ceftriaxone-calcium precipitation.
Microbiology

Mechanism of Action

Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both penicillinas and cephalosporinas, of Gram-negative and Gram-positive bacteria.

Mechanism of Resistance

Resistance to ceftriaxone is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.

Interaction with Other Antimicrobials

In an in vitro study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone.

Antibacterial Activity

Ceftriaxone has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE (1) section:

- **Gram-negative bacteria**
  - Acinetobacter calcoaceticus
  - Enterobacteraerogenes
  - Enterobacter cloacae
  - Escherichia coli
  - Haemophilus influenzae
  - Haemophilus parainfluenzae
  - Klebsiella oxytoca
  - Klebsiella pneumoniae
  - Moraxella catarrhalis
  - Morganellamorganii
  - Neisseria gonorrhoeae
  - Neisseria meningitidis
  - Proteus mirabilis
  - Proteus vulgaris
  - Pseudomonas aeruginosa
  - Serratiamarcescens

- **Gram-positive bacteria**
  - Staphylococcus aureus
  - Staphylococcus epidermidis
  - Streptococcus pneumoniae
  - Streptococcus pyogenes
  - Viridans group streptococci

- **Anaerobic bacteria**
  - Bacteroides fragilis
  - Clostridium species
  - Peptostreptococcus species

The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for ceftriaxone. However, the efficacy of ceftriaxone in treating clinical infections due to these microorganisms has not been established in adequate and well-
controlled clinical trials.

• **Gram-negative bacteria**

  *Citrobacter diversus*

  *Citrobacter freundii*

  *Providencia* species (including *Providencia rettgeri*)

  *Salmonella* species (including *Salmonella typhi*)

  *Shigella* species

• **Gram-positive bacteria**

  *Streptococcus agalactiae*

• **Anaerobic bacteria**

  *Porphyromonas (Bacteroides) melanogenicus*

  *Prevotella (Bacteroides) bivius*

**Susceptibility Test Methods**

When available, the clinical microbiology laboratory should provide the results of *in vitro* susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.

**Dilution techniques:** Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method.¹,³ The MIC values should be interpreted according to criteria provided in Table 5.

**Diffusion techniques:** Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method.²,³ This procedure uses paper disks impregnated with 30 mcg ceftriaxone to test the susceptibility of microorganisms to ceftriaxone. The disk diffusion interpretive criteria are provided in Table 5.

**Anaerobic techniques:** For anaerobic bacteria, the susceptibility to ceftriaxone as MICs can be determined by a standardized agar test method.³,⁴ The MIC values obtained should be interpreted according to the criteria provided in Table 5.

**Table 5. Susceptibility Test Interpretive Criteria for Ceftriaxone.**

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Minimum Inhibitory Concentrations (mcg/ml)</th>
<th>Disk Diffusion Zone Diameters (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(S) Susceptible</td>
<td>(I) Intermediate</td>
</tr>
<tr>
<td><strong>Enterobacteriaceae</strong>&lt;sup&gt;+&lt;/sup&gt;</td>
<td>≤ 1</td>
<td>2</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em>&lt;sup&gt;†,‡&lt;/sup&gt;</td>
<td>≤ 2</td>
<td>-</td>
</tr>
<tr>
<td><em>Neisseria gonorrhoeae</em>&lt;sup&gt;†&lt;/sup&gt;</td>
<td>≤ 0.25</td>
<td>-</td>
</tr>
<tr>
<td><em>Neisseria meningitidis</em>&lt;sup&gt;†&lt;/sup&gt;</td>
<td>≤ 0.12</td>
<td>-</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em>&lt;sup&gt;§&lt;/sup&gt; meningitis isolates</td>
<td>≤ 0.5</td>
<td>1</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em>&lt;sup&gt;§&lt;/sup&gt; non-meningitis isolates</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
### Table 6. Acceptable Quality Control Ranges for Ceftriaxone

<table>
<thead>
<tr>
<th>QC Strain</th>
<th>Minimum Inhibitory Concentrations (mcg/mL)</th>
<th>Disk Diffusion Zone diameters (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Escherichia coli</em> ATCC 25922</td>
<td>0.03 to 0.12</td>
<td>29 to 35</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em> ATCC 25923</td>
<td>-----------</td>
<td>22 to 28</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em> ATCC 29213</td>
<td>1 to 8</td>
<td>-----------</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em> ATCC 49247</td>
<td>0.06 to 0.25</td>
<td>31 to 39</td>
</tr>
<tr>
<td><em>Neisseria gonorrhoeae</em> ATCC 49226</td>
<td>0.004 to 0.015</td>
<td>39 to 51</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em> ATCC 27853</td>
<td>8 to 64</td>
<td>17 to 23</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em> ATCC 49619</td>
<td>0.03 to 0.12</td>
<td>30 to 35</td>
</tr>
<tr>
<td><em>Bacteroides fragilis</em> ATCC 25285 (agar method)</td>
<td>-----------</td>
<td>-----------</td>
</tr>
</tbody>
</table>

* Susceptibility interpretive criteria for *Enterobacteriaceae* are based on a dose of 1 gram IV q 24h. For isolates with intermediate susceptibility, use a dose of 2 grams IV q 24h in patients with normal renal function.
† For *Haemophilus influenzae*, susceptibility interpretive criteria are based on a dose of 2 grams IV every 24 hours in patients with normal renal function.
‡ The current absence of data on resistant isolates precludes defining any category other than ‘Susceptible’. If isolates yield MIC results other than susceptible, they should be submitted to a reference laboratory for additional testing.
§ Disc diffusion interpretive criteria for ceftriaxone discs against *Streptococcus pneumoniae* are not available, however, isolates of pneumococci with oxacillin zone diameters of ≥20 mm are susceptible (MIC ≤ 0.06 mcg/mL) to penicillin and can be considered susceptible to ceftriaxone. *Streptococcus pneumoniae* isolates should not be reported as penicillin (ceftriaxone) resistant or intermediate based solely on an oxacillin zone diameter of ≤ 19 mm. The ceftriaxone MIC should be determined for those isolates with oxacillin zone diameters ≤ 19 mm.

Susceptibility of staphylococci to ceftriaxone may be deduced from testing only penicillin and either cefoxitin or oxacillin.

A report of Susceptible indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration at the site of infection. A report of Intermediate indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentrations usually achievable at the infection site; other therapy should be selected.

Quality Control: Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test. Standard ceftriaxone powder should provide the following range of MIC values noted in Table 6. For the diffusion technique using the 30 mcg disk, the criteria in Table 6 should be achieved.
**INDICATIONS AND USAGE**

Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms:

**Lower Respiratory Tract Infections**
caused by *Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis* or *Serratia marcescens*.

**Acute Bacterial Otitis Media**
caused by *Streptococcus pneumoniae, Haemophilus influenzae* (including beta-lactamase producing strains) or *Moraxella catarrhalis* (including beta-lactamase producing strains).

NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES).

**Skin and Skin Structure Infections**
caused by *Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganellamorganii,^1^ Pseudomonas aeruginosa, Serratiamarcescens, Acinetobactercalcoaceticus, Bacteroidesfragilis^2^ or Peptostreptococcus species.

^1^ Efficacy for this organism in this organ system was studied in fewer than ten infections.

^2^ Efficacy for this organism in this organ system was studied in fewer than ten infections.

**Urinary Tract Infections (complicated and uncomplicated)**
caused by *Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganellamorganii* or *Klebsiella pneumoniae*.

**Uncomplicated Gonorrhea (cervical/urethral and rectal)**
caused by *Neisseria gonorrhoeae*, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of *Neisseria gonorrhoeae*.

**Pelvic Inflammatory Disease**
caused by *Neisseria gonorrhoeae*. Ceftriaxone sodium, like other cephalosporins, has no activity against *Chlamydia trachomatis*. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and *Chlamydia trachomatis* is one of the suspected pathogens, appropriate antichlamydial coverage should be added.

**Bacterial Septicemia**

caused by *Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae* or *Klebsiella pneumoniae*.

**Bone and Joint Infections**

caused by *Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae* or *Enterobacter* species.

**Intra-abdominal Infections**

caused by *Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium* species (Note: most strains of *Clostridium difficile* are resistant) or *Peptostreptococcus* species.

**Meningitis**

caused by *Haemophilus influenzae, Neisseria meningitidis* or *Streptococcus pneumoniae*. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by *Staphylococcus epidermidis* and *Escherichia coli*.

3 Efficacy for this organism in this organ system was studied in fewer than ten infections.

4 Efficacy for this organism in this organ system was studied in fewer than ten infections.

**Surgical Prophylaxis**

The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery.

When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure.

**CONTRAINDICATIONS**

**Hypersensitivity**

Ceftriaxone for injection is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. Patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone (see **WARNINGS – Hypersensitivity Reactions**).

**Neonates**
Premature neonates: Ceftriaxone for injection is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).

Hyperbilirubinemic neonates: Hyperbilirubinemic neonates should not be treated with ceftriaxone for injection. Ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients.

Neonates Requiring Calcium Containing IV Solutions

Ceftriaxone for injection is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CLINICAL PHARMACOLOGY, WARNINGS and DOSAGE AND ADMINISTRATION).

Cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium-containing fluids.

In some of these cases, the same intravenous infusion line was used for both ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. There have been no similar reports in patients other than neonates.

Lidocaine

Intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated. When lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection, exclude all contraindications to lidocaine. Refer to the prescribing information of lidocaine.

WARNINGS

Hypersensitivity Reactions

Before therapy with ceftriaxone for injection is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins and other beta-lactam agents or other drugs. This product should be given cautiously to penicillin and other beta-lactam agent-sensitive patients. Antibacterial drugs should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. Serious acute hypersensitivity reactions may require the use of subcutaneous epinephrine and other emergency measures.

As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions (i.e., anaphylaxis) have been reported. In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated.

Interaction with Calcium-Containing Products

Do not use diluents containing calcium, such as Ringer’s solution or Hartmann’s solution, to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. In vitro studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see CLINICAL PHARMACOLOGY, CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).

Clostridium difficile-Associated Diarrhea
*Clostridium difficile* associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ceftriaxone, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

*C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

**Hemolytic Anemia**

An immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials including ceftriaxone. Severe cases of hemolytic anemia, including fatalities, have been reported during treatment in both adults and children. If a patient develops anemia while on ceftriaxone, the diagnosis of a cephalosporin associated anemia should be considered and ceftriaxone stopped until the etiology is determined.

**PRECAUTIONS**

**Development of Drug-resistant Bacteria:** Prescribing ceftriaxone in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Prolonged use of ceftriaxone may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

**Patients with Renal or Hepatic Impairment:** Ceftriaxone is excreted via both biliary and renal excretion (see *CLINICAL PHARMACOLOGY*). Therefore, patients with renal failure normally require no adjustment in dosage when usual doses of ceftriaxone are administered.

Dosage adjustments should not be necessary in patients with hepatic dysfunction; however, in patients with both hepatic dysfunction and significant renal disease, caution should be exercised and the ceftriaxone dosage should not exceed 2 g daily.

Ceftriaxone is not removed by peritoneal- or hemodialysis. In patients undergoing dialysis no additional supplementary dosing is required following the dialysis. In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.

**Effect on Prothrombin Time:** Alterations in prothrombin times have occurred in patients treated with ceftriaxone. Monitor prothrombin time during ceftriaxone treatment in patients with impaired vitamin K synthesis or low vitamin K stores (eg, chronic hepatic disease and malnutrition). Vitamin K administration (10 mg weekly) may be necessary if the prothrombin time is prolonged before or during therapy.

Concomitant use of ceftriaxone with Vitamin K antagonists may increase the risk of bleeding. Coagulation parameters should be monitored frequently, and the dose of the anticoagulant adjusted accordingly, both during and after treatment with ceftriaxone (see *ADVERSE REACTIONS*).

**Gallbladder Pseudolithiasis:** Ceftriaxone-calcium precipitates in the gallbladder have been observed in patients receiving ceftriaxone. These precipitates appear on sonography as an echo without acoustical shadowing suggesting sludge or as an echo with acoustical shadowing which may be misinterpreted as gallstones. The probability of such precipitates appears to be greatest in pediatric patients. Patients may be asymptomatic or may develop symptoms of gallbladder disease. The condition appears to be reversible upon discontinuation of ceftriaxone sodium and institution of conservative management.
Discontinue ceftriaxone sodium in patients who develop signs and symptoms suggestive of gallbladder
disease and/or the sonographic findings described above.

**Urolithiasis and Post-Renal Acute Renal Failure**: Ceftriaxone-calcium precipitates in the urinary tract
have been observed in patients receiving ceftriaxone and may be detected as sonographic abnormalities.
The probability of such precipitates appears to be greatest in pediatric patients. Patients may be
asymptomatic or may develop symptoms of urolithiasis, and ureteral obstruction and post-renal acute
renal failure. The condition appears to be reversible upon discontinuation of ceftriaxone sodium and
institution of appropriate management. Ensure adequate hydration in patients receiving ceftriaxone.
Discontinue ceftriaxone in patients who develop signs and symptoms suggestive of urolithiasis,
oliguria or renal failure and/or the sonographic findings described above.

**Pancreatitis**: Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported in
patients treated with ceftriaxone. Most patients presented with risk factors for biliary stasis and biliary
sludge (preceding major therapy, severe illness, total parenteral nutrition). A cofactor role of
ceftriaxone-related biliary precipitation cannot be ruled out.

**Information for Patients**

- Patients should be counseled that antibacterial drugs including ceftriaxone for injection should
  only be used to treat bacterial infections. They do not treat viral infections (e.g., common cold).
- When ceftriaxone for injection is prescribed to treat a bacterial infection, patients should be told
  that although it is common to feel better early in the course of therapy, the medication should be
taken exactly as directed. Skipping doses or not completing the full course of therapy may (1)
decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria
will develop resistance and will not be treatable by ceftriaxone for injection or other antibacterial
drugs in the future.
- Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is
discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and
bloody stools (with or without stomach cramps and fever) even as late as two or more months after
having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as
soon as possible.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

**Carcinogenesis**

Considering the maximum duration of treatment and the class of the compound, carcinogenicity studies
with ceftriaxone in animals have not been performed. The maximum duration of animal toxicity studies
was 6 months.

**Mutagenesis**

Genetic toxicology tests included the Ames test, a micronucleus test and a test for chromosomal
aberrations in human lymphocytes cultured in vitro with ceftriaxone. Ceftriaxone showed no potential
for mutagenic activity in these studies.

**Impairment of Fertility**

Ceftriaxone produced no impairment of fertility when given intravenously to rats at daily doses up to
586 mg/kg/day, approximately 20 times the recommended clinical dose of 2 g/day.

**Pregnancy**

Teratogenic Effects
Pregnancy Category B

Reproductive studies have been performed in mice and rats at doses up to 20 times the usual human dose and have no evidence of embryotoxicity, fetotoxicity or teratogenicity. In primates, no embryotoxicity or teratogenicity was demonstrated at a dose approximately 3 times the human dose.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nonteratogenic Effects

In rats, in the Segment I (fertility and general reproduction) and Segment III (perinatal and postnatal) studies with intravenously administered ceftriaxone, no adverse effects were noted on various reproductive parameters during gestation and lactation, including postnatal growth, functional behavior and reproductive ability of the offspring, at doses of 586 mg/kg/day or less.

Nursing Mothers

Low concentrations of ceftriaxone are excreted in human milk. Caution should be exercised when ceftriaxone is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of ceftriaxone in neonates, infants and pediatric patients have been established for the dosages described in the DOSAGE AND ADMINISTRATION section. In vitro studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin. Ceftriaxone should not be administered to hyperbilirubinemic neonates, especially prematures (see CONTRAINDICATIONS).

Geriatric Use

Of the total number of subjects in clinical studies of ceftriaxone, 32% were 60 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

The pharmacokinetics of ceftriaxone were only minimally altered in geriatric patients compared to healthy adult subjects and dosage adjustments are not necessary for geriatric patients with ceftriaxone dosages up to 2 grams per day provided there is no severe renal and hepatic impairment (see CLINICAL PHARMACOLOGY).

Influence on Diagnostic Tests

In patients treated with ceftriaxone the Coombs’ test may become positive. Ceftriaxone for injection, like other antibacterial drugs, may result in positive test results for galactosemia.

Nonenzymatic methods for the glucose determination in urine may give false-positive results. For this reason, urine-glucose determination during therapy with ceftriaxone should be done enzymatically.

The presence of ceftriaxone may falsely lower estimated blood glucose values obtained with some blood glucose monitoring systems. Please refer to instructions for use for each system. Alternative testing methods should be used if necessary.

ADVERSE REACTIONS

Ceftriaxone is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to ceftriaxone therapy or of uncertain etiology, were observed:
Local Reactions
pain, induration and tenderness was 1% overall. Phlebitis was reported in <1% after IV administration. The incidence of warmth, tightness or induration was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL.

General Disorders and Administration Site Conditions
injection site pain (0.6%).

Hypersensitivity
rash (1.7%). Less frequently reported (<1%) were pruritus, fever or chills.

Infections and Infestations
genital fungal infection (0.1%)

Hematologic
eosinophilia (6%), thrombocytosis (5.1%) and leukopenia (2.1%). Less frequently reported (<1%) were anemia, hemolytic anemia, neutropenia, lymphopenia, thrombocytopenia and prolongation of the prothrombin time.

Blood and Lymphatic Disorders
granulocytopenia (0.9%), coagulopathy (0.4%)

Gastrointestinal
diarrhea/loose stools (2.7%). Less frequently reported (<1%) were nausea or vomiting, and dysgeusia. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS).

Hepatic
elevations of aspartate aminotransferase (AST) (3.1%) or alanine aminotransferase (ALT) (3.3%). Less frequently reported (<1%) were elevations of alkaline phosphatase and bilirubin.

Renal
elevations of the BUN (1.2%). Less frequently reported (<1%) were elevations of creatinine and the presence of casts in the urine.

Central Nervous System
headache or dizziness were reported occasionally (<1%).

Genitourinary
moniliasis or vaginitis were reported occasionally (<1%).

Miscellaneous
diaphoresis and flushing were reported occasionally (<1%).

Investigations
blood creatinine increased (0.6%).

Other rarely observed adverse reactions (<0.1%) include abdominal pain, agranulocytosis, allergic pneumonitis, anaphylaxis, basophilia, biliary lithiasis, bronchospasm, colitis, dyspepsia, epistaxis, flatulence, gallbladder sludge, glycosuria, hematuria, jaundice, leukocytosis, lymphocytosis,
monocytosis, nephrolithiasis, palpitations, a decrease in the prothrombin time, renal precipitations, seizures, and serum sickness.

**Postmarketing Experience**

In addition to the adverse reactions reported during clinical trials, the following adverse experiences have been reported during clinical practice in patients treated with ceftriaxone. Data are generally insufficient to allow an estimate of incidence or to establish causation.

A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone and calcium-containing fluids. In some of these cases, the same intravenous infusion line was used for both ceftriaxone and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. At least one fatality has been reported in a neonate in whom ceftriaxone and calcium-containing fluids were administered at different time points via different intravenous lines; no crystalline material was observed at autopsy in this neonate. There have been no similar reports in patients other than neonates.

Gastrointestinal

pancreatitis, stomatitis and glossitis.

Genitourinary

oliguria, ureteric obstruction, post-renal acute renal failure.

Dermatologic

exanthema, allergic dermatitis, urticaria, edema; acute generalized exanthematous pustulosis (AGEP) and isolated cases of severe cutaneous adverse reactions (erythema multiforme, Stevens-Johnson syndrome or Lyell’s syndrome/toxic epidermal necrolysis) have been reported.

Hematological Changes

isolated cases of agranulocytosis (< 500/mm³) have been reported, most of them after 10 days of treatment and following total doses of 20 g or more.

Nervous System Disorders

convulsion

Other, Adverse Reactions

symptomatic precipitation of ceftriaxone calcium salt in the gallbladder, kernicterus, oliguria, and anaphylactic or anaphylactoid reactions.

**Cephalosporin Class Adverse Reactions**

In addition to the adverse reactions listed above which have been observed in patients treated with ceftriaxone, the following adverse reactions and altered laboratory test results have been reported for cephalosporin class antibiotics:

**Adverse Reactions**

Allergic reactions, drug fever, serum sickness-like reaction, renal dysfunction, toxic nephropathy, reversible hyperactivity, hypertonia, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, and superinfection.

**Altered Laboratory Tests**

Positive direct Coombs’ test, false-positive test for urinary glucose, and elevated LDH (see **PRECAUTIONS**).
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see DOSAGE AND ADMINISTRATION). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

OVERDOSAGE
In the case of overdosage, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdosage should be symptomatic.

DOSAGE AND ADMINISTRATION
Ceftriaxone in the ADD-Vantage® Vial is intended for intravenous infusion only, after dilution with appropriate volume of ADD-Vantage® diluent solution.

Do not use diluents containing calcium, such as Ringer’s solution or Hartmann’s solution, to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same IV administration line.

Ceftriaxone must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see WARNINGS).

There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (IV or oral).

Neonates
Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone for injection. Ceftriaxone is contraindicated in premature neonates (see CONTRAINDICATIONS).

Ceftriaxone is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CONTRAINDICATIONS).

Intravenous doses should be given over 60 minutes in neonates to reduce the risk of bilirubin encephalopathy.

Pediatric Patients
For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams.

For the treatment of acute bacterial otitis media, a single intramuscular dose of 50 mg/kg (not to exceed 1 gram) is recommended (see INDICATIONS AND USAGE). (The above is for informational purposes only. Ceftriaxone in ADD-Vantage® vials is not intended for intramuscular use.)

For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams.

In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is
recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days.

**Adults**

The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 grams.

If *Chlamydia trachomatis* is a suspected pathogen, appropriate antichlamydial coverage should be added, because ceftriaxone sodium has no activity against this organism.

For the treatment of uncomplicated gonococcal infections, a single intramuscular dose of 250 mg is recommended. (The above is for informational purposes only. Ceftriaxone in ADD-Vantage® vials is not intended for intramuscular use.)

For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously ½ to 2 hours before surgery is recommended.

Generally, ceftriaxone therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required.

When treating infections caused by *Streptococcus pyogenes*, therapy should be continued for at least 10 days.

No dosage adjustment is necessary for patients with impairment of renal or hepatic function (see PRECAUTIONS).

The dosages recommended for adults require no modification in elderly patients, up to 2 g per day, provided there is no severe renal and hepatic impairment (see PRECAUTIONS).

**Directions for Use**

**Intravenous Administration**

Ceftriaxone should be administered intravenously by infusion over a period of 30 minutes, except in neonates where administration over 60 minutes is recommended to reduce the risk of bilirubin encephalopathy.

ADD-Vantage® Vials for IV Use Only contain ceftriaxone sodium equivalent to 1 g or 2 g ceftriaxone to be used with 50 mL or 100 mL of 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, in the ADD-Vantage® Flexible Diluent Container. (See Instructions For Use of the ADD-Vantage® System at the end of this package insert.)

**Compatibility and Stability**

Do not use diluents containing calcium, such as Ringer’s solution or Hartmann’s solution, to reconstitute ceftriaxone for injection vials or to further dilute a reconstituted vial for IV administration. Particulate formation can result.

Ceftriaxone has been shown to be compatible with Flagyl® IV (metronidazole hydrochloride). The concentration should not exceed 5 to 7.5 mg/mL metronidazole hydrochloride with ceftriaxone 10 mg/mL as an admixture. The admixture is stable for 24 hours at room temperature only in 0.9% sodium chloride injection or 5% dextrose in water (D5W). No compatibility studies have been conducted with the Flagyl® IV RTU® (metronidazole) formulation or using other diluents. Metronidazole at concentrations greater than 8 mg/mL will precipitate. Do not refrigerate the admixture as precipitation will occur.

Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with ceftriaxone in admixtures. When any of these drugs are to be administered concomitantly with ceftriaxone by intermittent intravenous infusion, it is recommended that they be given sequentially, with thorough
flushing of the intravenous lines (with one of the compatible fluids) between the administrations.

Ceftriaxone for injection solutions should not be physically mixed with or piggybacked into solutions containing other antimicrobial drugs or into diluent solutions other than those listed above, due to possible incompatibility (see WARNINGS).

Ceftriaxone sodium sterile powder should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] and protected from light. After reconstitution, protection from normal light is not necessary. The color of solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used.

After the indicated stability time periods, unused portions of solutions should be discarded.

NOTE: Parenteral drug products should be inspected visually for particulate matter before administration. ADD-Vantage® Vials – Ceftriaxone for Injection Units: See Instructions For Use of the ADD-Vantage® System at the end of this package insert.

ANIMAL PHARMACOLOGY

Concretions consisting of the precipitated calcium salt of ceftriaxone have been found in the gallbladder bile of dogs and baboons treated with ceftriaxone.

These appeared as a gritty sediment in dogs that received 100 mg/kg/day for 4 weeks. A similar phenomenon has been observed in baboons but only after a protracted dosing period (6 months) at higher dose levels (335 mg/kg/day or more). The likelihood of this occurrence in humans is considered to be low, since ceftriaxone has a greater plasma half-life in humans, the calcium salt of ceftriaxone is more soluble in human gallbladder bile and the calcium content of human gallbladder bile is relatively low.

HOW SUPPLIED

Ceftriaxone for injection, USP is supplied as a sterile, white to yellowish crystalline powder in ADD-Vantage® Vials as follows:

ADD-Vantage® Vials containing 1 g equivalent to ceftriaxone. Box of 10 (NDC 0409-7333-49).
ADD-Vantage® Vials containing 2 g equivalent to ceftriaxone. Box of 10 (NDC 0409-7336-49).

Storage Prior to Reconstitution

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.

CLINICAL STUDIES

Clinical Trials in Pediatric Patients With Acute Bacterial Otitis Media

(The following is for informational purposes only. Ceftriaxone in ADD-Vantage® vials is not intended for intramuscular use.) In two adequate and well-controlled US clinical trials a single IM dose of ceftriaxone was compared with a 10 day course of oral antibiotic in pediatric patients between the ages of 3 months and 6 years. The clinical cure rates and statistical outcome appear in the table below:

<table>
<thead>
<tr>
<th>Study Day</th>
<th>Ceftriaxone Single Dose</th>
<th>Comparator-10 Days of Oral Therapy</th>
<th>95% Confidence Interval</th>
<th>Statistical Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Efficacy in Evaluable Population</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
An open-label bacteriologic study of ceftriaxone without a comparator enrolled 108 pediatric patients, 79 of whom had positive baseline cultures for one or more of the common pathogens. The results of this study are tabulated as follows:

Week 2 and 4 Bacteriologic Eradication Rates in the Per Protocol Analysis in the Roche Bacteriologic Study by pathogen:

Table 8. Bacteriologic Eradication Rates by Pathogen

<table>
<thead>
<tr>
<th>Organism</th>
<th>Study Day 13 to 15</th>
<th>Study Day 30+2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. Analyzed</td>
<td>No. Erad. (%)</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>38</td>
<td>32 (84)</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>33</td>
<td>28 (85)</td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em></td>
<td>15</td>
<td>12 (80)</td>
</tr>
</tbody>
</table>

REFERENCES


Instructions For Use of the ADD-Vantage® System

To Open Diluent Container:

Peel overwrap from the corner and remove container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the
solution quality or safety. The opacity will diminish gradually.

**To Assemble Vial and Flexible Diluent Container (Use Aseptic Technique):**

1. Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:
2. To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (SEE FIGURE 1.), then pull straight up to remove the cap. (SEE FIGURE 2.) NOTE: Do not access vial with syringe.

![Fig. 1](image1)

3. To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover. (SEE FIGURE 3.)
4. Screw the vial into the vial port until it will go no further. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately 1/2 turn (180°) after the first audible click. (SEE FIGURE 4.) The clicking sound does not assure a seal; the vial must be turned as far as it will go. NOTE: Once vial is seated, do not attempt to remove. (SEE FIGURE 4.)

![Fig. 2](image2)

![Fig. 3](image3)
5. Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.

To Reconstitute the Drug:

1. Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.
2. With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container. (SEE FIGURE 5.)
3. Pull the inner cap from the drug vial. (SEE FIGURE 6.) Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix.
4. Mix container contents thoroughly and use within the specified time.
Preparation for Administration (Use Aseptic Technique):

1. Confirm the activation and admixture of vial contents.
2. Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.
3. Close flow control clamp of administration set.
4. Remove cover from outlet port at bottom of container.
5. Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.
   NOTE: See full directions on administration set carton.
6. Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.
7. Squeeze and release drip chamber to establish proper fluid level in chamber.
8. Open flow control clamp and clear air from set. Close clamp.
9. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
10. Regulate rate of administration with flow control clamp.

**WARNING:** Do not use flexible container in series connections.

**STABILITY:** The ADD-Vantage® System is designed to minimize drug waste by allowing the drug and diluent to be mixed at bedside just prior to administration. However, in those rare instances where the admixed unit cannot be administered within the specified time, ceftriaxone ADD-Vantage® units may be safely stored under the following conditions:

<table>
<thead>
<tr>
<th>Diluent</th>
<th>Concentration</th>
<th>Room Temperature (25°C)</th>
<th>Refrigeration (4°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.9% Sodium Chloride Solution</td>
<td>10 mg/mL to 40 mg/mL</td>
<td>2 days</td>
<td>10 days</td>
</tr>
<tr>
<td>5% Dextrose Solution</td>
<td>10 mg/mL to 40 mg/mL</td>
<td>2 days</td>
<td>10 days</td>
</tr>
</tbody>
</table>

Reconstituted ADD-Vantage® units should *not* be stored in a frozen state (-20°C).

Flagyl® is a registered trademark of G.D. Searle & Co.

NOVAPLUS is a registered trademark of Novation, LLC.

ADD-Vantage® is a trademark of Hospira, Inc.

Printed in Austria
07-2015M
46165448
EN-3977
Manufactured by Sandoz GmbH, Kundl, Austria

1 gram Label
NDC 0409-7333-49
Ceftriaxone for Injection, USP
1 gram
For I.V. Use
Single Use ADD-Vantage® Vial
Rx only
NOVAPLUS®

2 gram Label
Ceftriaxone for Injection, USP
2 grams
For I.V. Use
Single Use ADD-Vantage® Vial
Rx only
NOVAPLUS®

CEFTRIAXONE SODIUM
ceftriaxone sodium injection, powder, for solution

<table>
<thead>
<tr>
<th>Product Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Type</strong></td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
</tr>
<tr>
<td><strong>Item Code (Source)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active Ingredient/Active Moiety</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ingredient Name</strong></td>
</tr>
<tr>
<td>CEFTRIAXONE SODIUM (UNII: 023Z5BR09K) (CEFTRIAXONE - UNII:75J73V1629)</td>
</tr>
</tbody>
</table>

Packaging
### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:0409-7336</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Type</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTRAVENOUS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEFTRIAXONE SODIUM (UNII: 023Z5BR09K) (CEFTRIAXONE - UNII:75J73V1629)</td>
<td>CEFTRIAXONE</td>
<td>2 g</td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0409-7333-49</td>
<td>10 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1 in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA065204</td>
<td>05/03/2005</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Hospira, Inc (141588017)

Revised: 7/2015  Hospira, Inc